Compare BBWI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | LGND |
|---|---|---|
| Founded | 1963 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 1994 | N/A |
| Metric | BBWI | LGND |
|---|---|---|
| Price | $18.71 | $196.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | $25.61 | ★ $245.86 |
| AVG Volume (30 Days) | ★ 5.7M | 186.4K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $7,291,000,000.00 | N/A |
| Revenue This Year | N/A | $1.50 |
| Revenue Next Year | $2.19 | $18.28 |
| P/E Ratio | ★ $6.02 | $76.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.28 | $93.58 |
| 52 Week High | $34.29 | $227.92 |
| Indicator | BBWI | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 46.00 |
| Support Level | $14.28 | $179.55 |
| Resistance Level | $20.36 | $207.72 |
| Average True Range (ATR) | 1.00 | 10.36 |
| MACD | -0.09 | -1.99 |
| Stochastic Oscillator | 48.09 | 27.09 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,900 retail stores), similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.